No Impact of Corticosteroid Use During the Acute Phase on Persistent Symptoms Post-COVID-19

Persistent COVID-19 symptoms may be related to residual inflammation, but no preventive treatment has been evaluated. This study aimed to analyze, in a prospective cohort, whether corticosteroid use in the acute phase of COVID-19 in hospitalized patients may reduce the risk of persistent COVID-19 sy...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of general medicine Vol. 15; pp. 6645 - 6651
Main Authors Ko, Adrien Chan Sui, Candellier, Alexandre, Mercier, Marie, Joseph, Cedric, Carette, Hortense, Basille, Damien, Lion-Daolio, Sylvie, Devaux, Stephanie, Schmit, Jean-Luc, Lanoix, Jean-Philippe, Andrejak, Claire
Format Journal Article
LanguageEnglish
Published Dove Medical Press Limited 01.01.2022
Dove Press ; Taylor & Francis
Dove
Dove Medical Press
Subjects
Analysis
asthenia
corticosteroid use
Corticosteroids
covid-19
Hospital patients
Human health and pathology
Inflammation
Life Sciences
long covid-19
Medicine, Preventive
persistent symptoms
Preventive health services
Short Report
France
COVID-19
long COVID-19
corticosteroid use
persistent symptoms
asthenia
Online AccessGet full text

Cover

More Information
Summary:Persistent COVID-19 symptoms may be related to residual inflammation, but no preventive treatment has been evaluated. This study aimed to analyze, in a prospective cohort, whether corticosteroid use in the acute phase of COVID-19 in hospitalized patients may reduce the risk of persistent COVID-19 symptoms. A total of 306 discharged patients, including 112 (36.6%) from the ICU, completed a structured face-to-face assessment 4 months after admission. Of these, 193 patients (63.1%) had at least one persistent symptom, mostly dyspnea (38.9%) and asthenia (37.6%). One-hundred and four patients have received corticosteroids. In multivariable adjusted regression analysis, corticosteroid use was not associated with the presence of at least one symptom (OR=1.00, 95% CI: 0.58-1.71, p=0.99) or with the number of persistent symptoms (p=0.74). Corticosteroid use remained ineffective when analyzing the ICU subpopulation separately. Our study suggests that corticosteroid use had no impact on persistent symptoms after COVID-19 in discharged patients. Keywords: COVID-19, persistent symptoms, corticosteroid use, long COVID-19, asthenia
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work
ISSN:1178-7074
1178-7074
DOI:10.2147/IJGM.S367273